Abaxis Announces Licensing of Lyophilization Technology to bioMerieux
21 3월 2006 - 8:30PM
PR Newswire (US)
UNION CITY, Calif., March 21 /PRNewswire-FirstCall/ -- Abaxis, Inc.
(NASDAQ:ABAX), a medical products company manufacturing
point-of-care blood analysis systems, announced today that it has
completed an agreement to license a portion of its patent portfolio
covering lyophilization technology to bioMerieux SA. "Our Orbos
lyophilization technology, through the freeze drying of reagents in
small quantities, enables efficient manufacturing of reagents in a
convenient and stable format. This license with bioMerieux once
again shows that our Orbos technology is quickly becoming a
standard format for reagent utilization in molecular diagnostics,"
said Kenneth Aron, Ph.D., Vice-President of R&D at Abaxis. "We
now have several major companies utilizing our Orbos lyophilization
technology. All of these companies have recognized the utility of
our freeze-drying solution and are committed to utilizing our
technology in a number of their product lines." Dr. Aron continued,
"We see significant opportunities for further licensing in the
fields of molecular diagnostics and environmental monitoring. These
licensing opportunities are particularly attractive to Abaxis since
these fields are complementary to our own but in no way compete
with our core business of clinical chemistry. Since we get
additional recurring revenue for Abaxis, these licenses all
represent classic win-win scenarios for us and for our present and
future licensees." About Abaxis Abaxis develops, manufactures and
markets portable blood analysis systems for use in any veterinary
or human patient-care setting to provide clinicians with rapid
blood constituent measurements. The system consists of a compact,
6.9 kilogram (15 pounds), portable analyzer and a series of
single-use plastic discs, called reagent discs that contain all the
chemicals required to perform a panel of up to 13 tests on
veterinary patients and 14 tests on human patients. The system can
be operated with minimal training and performs multiple routine
tests on whole blood, serum or plasma samples. The system provides
test results in less than 14 minutes with the precision and
accuracy equivalent to a clinical laboratory analyzer. This press
release includes statements that constitute "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 (the "Reform Act"). Abaxis claims the protection
of the safe-harbor for forward-looking statements contained in the
Reform Act. These forward-looking statements are often
characterized by the terms "may", "believes", "projects",
"expects", or "anticipates", and do not reflect historical facts.
Specific forward-looking statements contained in this press release
include, but are not limited to, risks and uncertainties related to
fluctuations in the Company's share price, the market acceptance of
the Company's products and the continuing development of its
products, required United States Food and Drug Administration
("FDA") clearance and other government approvals, risks associated
with manufacturing and distributing its products on a commercial
scale free of defects, risks related to the introduction of new
instruments manufactured by third parties, risks associated with
entering the human diagnostic market on a larger scale, risks
related to the protection of the Company's intellectual property or
claims of infringement of intellectual property asserted by third
parties, risks involved in carrying of inventory, risks associated
with the ability to attract, train and retain competent sales
personnel, general market conditions, competition and other risks
detailed from time to time in Abaxis' periodic reports filed with
the United States Securities and Exchange Commission.
Forward-looking statements speak only as of the date the statement
was made. Abaxis does not undertake and specifically disclaims any
obligation to update any forward-looking statements. Contact: Clint
Severson Lytham Partners, LLC Chief Executive Officer Joe Dorame,
Robert Blum, Joe Diaz Abaxis, Inc. 602-889-9700 510-675-6500
DATASOURCE: Abaxis, Inc. CONTACT: Clint Severson, Chief Executive
Officer of Abaxis, Inc., +1-510-675-6500; or Joe Dorame, or Robert
Blum, or Joe Diaz, all of Lytham Partners, LLC, +1-602-889-9700,
for Abaxis, Inc.
Copyright
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Abaxis, Inc. (delisted) (NASDAQ:ABAX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024